A pilot study evaluating a new questionnaire for prostatic symptom scoring, the SPSS, and its sensitivity as constructed to objective measures of outflow obstruction

Yano, Masataka; Kitahara, Satoshi; Yasuda, Kosaku; Yamanishi, Tomonori; Nakai, Hideo; Yanagisawa, Ryouzo; Morozumi, Makoto; Homma, Yukio

doi:10.1111/j.1442-2042.2004.00796.x

Cited by 3 publications

(3 citation statements)

References 30 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ALthough the IPSS is generally used to assess the subjective symptoms associated with BPH, one study documented that the seven questions in this scale are insufficient. 15 The LUTDSS represented the main assessment item in the present study and was determined using the seven IPSS questions plus a question dealing with a 'small quantity at one-time urination'.…”

Section: Discussionmentioning

confidence: 99%

Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study

Yokoyama¹,

Kumon²,

Nasu³

et al. 2006

Int J of Urology

View full text Add to dashboard Cite

Background:The present study investigated the efficacy, safety, and utility of starting an α 1d -selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Methods: In this prospective comparative study, the subjects comprised 153 patients with LUTS associated with BPH. Patients were randomized to receive either 25 mg/day (Group LD) or 75 mg/day (Group HD) of naftopidil for 4 weeks. The lower urinary tract disease symptom score (LUTDSS), the International Prostate Symptom Score (IPSS), the Quality of life assessment index, the maximum flow rate (Q max ), and the residual urine volume were compared between the groups. Results: In both groups, the LUTDSS and the IPSS were significantly improved at the endpoint and no significant intergroup differences were identified. However, the improvement in the Q max was significantly better for Group HD than for Group LD. The overall efficacy did not differ significantly between the groups. The degree of improvement in voiding symptoms and LUTDSS among patients with moderate symptoms was significantly greater for Group HD than for Group LD. The frequency of adverse reactions did not differ significantly between the groups. Conclusions: Starting administration at 75 mg/day rather than 25mg/day is helpful for LUTS associated with BPH for patients with moderate symptoms, particularly in improving voiding symptoms. The 75 mg/day administration was considered to be a recommendable therapeutic dose in some patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study

Yokoyama¹,

Kumon²,

Nasu³

et al. 2006

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…11 There is weak or almost no correlation between LUTS and other clinical indicators such as prostate volume, urinary flow rate, residual urine volume, or the degree of infravesical (outflow) obstruction. 12,13 Within the individuals of the particular disorder, however, LUTS and urodynamic findings are modestly correlated.…”

Section: Luts Comprise Important Elements In the Diagnosis And Assessmentioning

confidence: 99%

Clinical guideline for male lower urinary tract symptoms

et al. 2009

Self Cite

View full text Add to dashboard Cite

This article is a shortened version of the clinical guideline for lower urinary tract symptoms (LUTS), which has been developed in Japan for symptomatic men aged 50 years and over irrespective of presumed diagnoses. The guideline was formed on the PubMed database between 1995 and 2007 and other relevant sources. The causes of male LUTS are diverse and attributable to diseases/dysfunctions of the lower urinary tract, prostate, nervous system, and other organ systems, with benign prostatic hyperplasia, bladder dysfunction, polyuria, and their combination being most common. The mandatory assessment should comprise medical history, physical examination, urinalysis, and measurement of serum prostate-specific antigen. Symptom and quality of life questionnaires, bladder diary, residual urine measurement, urine cytology, urine culture, measurement of serum creatinine, and urinary tract ultrasonography would be optional tests. The Core Lower Urinary Tract Symptom Score Questionnaire may be useful in quickly capturing important symptoms. Severe symptoms, pain symptoms, and other clinical problems would indicate urological referral. One should be careful not to overlook underlying diseases such as infection or malignancy. The treatment should be initiated with conservative therapy and/or medicine such as a1-blockers. Treatment with anticholinergic agents should be reserved only for urologists, considering the risk of urinary retention. The present guideline should help urologists and especially non-urologists treat men with LUTS.

show abstract

“…The current concept of TD was first addressed on the ICS male questionnaire and has been defined by ICS recommendations in 2002 [ 4 , 7 ]. Before this definition, the studies performed in 1990s used various definitions of TD [ 12 – 16 ]. Moreover, several reports have regarded TD as an initial or mild form of post-void dribbling [ 13 – 15 ].…”

Section: Discussionmentioning

confidence: 99%

Terminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion

et al. 2015

View full text Add to dashboard Cite

BackgroundTerminal dribbling is one of the lower urinary tract symptoms (LUTS) that has not been widely studied. The aim of this study was to investigate the associations between terminal dribbling (TD) and other parameters such as International Prostate Symptom Score (IPSS) and intravesical prostatic protrusion (IPP).MethodsMedical records of male patients with LUTS aged 40 years and older were prospectively collected. Data regarding TD defined by the International Continence Society standardization subcommittee, IPSS, prostate-specific antigen, total prostate volume, and IPP on transrectal ultrasonography were obtained. TD was confirmed by the subsequent uroflowmetry (uroflowmetry-confirmed TD). Logistic regression analysis was performed to identify the parameters affecting TD and uroflowmetry-confirmed TD.ResultsAmong the 578 men, 226 patients (39.1 %) complained of TD and 157 patients (27.2 %) had objective findings of TD on uroflowmetry. In the logistic regression analysis, IPSS voiding subscore were correlated with TD (Odds ratio 1.06). In addition, IPP was the only significant risk factor for uroflowmetry-confirmed TD (Odds ratio 2.83). Each question of IPSS is not correlated with TD or uroflowmetry-confirmed TD.ConclusionsWhile the symptom of TD is well correlated with IPSS voiding subscore, objective evidence of TD on uroflowmetry had strong correlation with IPP. TD should be investigated further to reveal its clinical impact and guide a proper management.

show abstract

A pilot study evaluating a new questionnaire for prostatic symptom scoring, the SPSS, and its sensitivity as constructed to objective measures of outflow obstruction

Cited by 3 publications

References 30 publications

Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study

Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study

Clinical guideline for male lower urinary tract symptoms

Terminal dribbling in male patients with lower urinary tract symptoms: relationship with International Prostate Symptom Score and with intravesical prostatic protrusion

Contact Info

Product

Resources

About